> top > docs > PubMed:33041824 > annotations

PubMed:33041824 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 508-515 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T2 508-515 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T3 547-554 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T4 547-554 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T5 737-744 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T6 737-744 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T7 753-760 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T8 753-760 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T9 879-886 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T10 879-886 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T11 919-926 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T12 919-926 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T13 935-942 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T14 935-942 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T15 1013-1020 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T16 1013-1020 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T17 1143-1150 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T18 1143-1150 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-98 Sentence denotes Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications:
T2 99-132 Sentence denotes A Review of the Current Evidence.
T3 133-245 Sentence denotes The impact of the COVID-19 pandemic has been dramatic worldwide, with China, Italy, and now US at its epicenter.
T4 246-385 Sentence denotes Researchers and clinicians are studying and testing different approaches in the attempt to prevent the infection and minimize its severity.
T5 386-599 Sentence denotes Major efforts are focused on optimizing mechanical ventilation, antiviral, and supportive treatment; however, the role of heparin and low molecular weight (LMW) heparin in this setting has been largely overlooked.
T6 600-1101 Sentence denotes This review summarizes the available evidence about the role of heparan sulfate as a key entry mechanism for SARS-CoV-2; the efficacy of heparin and LMW heparin in counteracting its entry into the cell, the recent experimental findings obtained in in vitro studies using the LMW heparin enoxaparin Inhixa®, the role of heparin and LMW heparin in modulating the cytokine storm, and the evidence for the use of LMW heparin in the prevention and treatment of the thromboembolic complications of COVID-19.
T7 1102-1208 Sentence denotes The available evidence suggests that LMW heparin appears as a promising tool in the treatment of COVID-19.
T8 1209-1381 Sentence denotes Whether its systematic use is associated with a reduction in complications and ultimately mortality of these patients is being tested in several studies starting worldwide.
T1 0-98 Sentence denotes Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications:
T2 99-132 Sentence denotes A Review of the Current Evidence.
T3 133-245 Sentence denotes The impact of the COVID-19 pandemic has been dramatic worldwide, with China, Italy, and now US at its epicenter.
T4 246-385 Sentence denotes Researchers and clinicians are studying and testing different approaches in the attempt to prevent the infection and minimize its severity.
T5 386-599 Sentence denotes Major efforts are focused on optimizing mechanical ventilation, antiviral, and supportive treatment; however, the role of heparin and low molecular weight (LMW) heparin in this setting has been largely overlooked.
T6 600-1101 Sentence denotes This review summarizes the available evidence about the role of heparan sulfate as a key entry mechanism for SARS-CoV-2; the efficacy of heparin and LMW heparin in counteracting its entry into the cell, the recent experimental findings obtained in in vitro studies using the LMW heparin enoxaparin Inhixa®, the role of heparin and LMW heparin in modulating the cytokine storm, and the evidence for the use of LMW heparin in the prevention and treatment of the thromboembolic complications of COVID-19.
T7 1102-1208 Sentence denotes The available evidence suggests that LMW heparin appears as a promising tool in the treatment of COVID-19.
T8 1209-1381 Sentence denotes Whether its systematic use is associated with a reduction in complications and ultimately mortality of these patients is being tested in several studies starting worldwide.

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 508-515 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T2 547-554 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T3 664-679 Body_part denotes heparan sulfate http://purl.org/sig/ont/fma/fma63023
T4 737-744 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T5 753-760 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T6 797-801 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T7 879-886 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T8 919-926 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T9 935-942 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T10 961-969 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T11 1013-1020 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T12 1143-1150 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 32-40 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 41-50 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T3 151-159 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 349-358 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T5 709-717 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T6 1092-1100 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 1199-1207 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 99-100 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 169-172 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T3 290-297 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T4 404-411 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T5 571-574 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T6 683-684 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 797-801 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T8 1162-1163 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 1255-1256 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 1336-1342 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 7-17 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T2 450-459 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T3 508-515 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T4 547-554 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T5 664-679 Chemical denotes heparan sulfate http://purl.obolibrary.org/obo/CHEBI_28815
T6 664-671 Chemical denotes heparan http://purl.obolibrary.org/obo/CHEBI_24500
T7 672-679 Chemical denotes sulfate http://purl.obolibrary.org/obo/CHEBI_16189
T8 737-744 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T9 753-760 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T10 879-886 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T11 919-926 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T12 935-942 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T13 1013-1020 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T14 1143-1150 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
4 7-17 Chemical denotes Enoxaparin MESH:D017984
5 32-40 Disease denotes COVID-19 MESH:C000657245
6 41-50 Disease denotes Infection MESH:D007239
7 62-97 Disease denotes Thromboembolic Venous Complications MESH:D054556
26 151-159 Disease denotes COVID-19 MESH:C000657245
27 349-358 Disease denotes infection MESH:D007239
28 508-515 Chemical denotes heparin MESH:D006493
29 520-540 Chemical denotes low molecular weight
30 547-554 Chemical denotes heparin MESH:D006493
31 709-719 Species denotes SARS-CoV-2 Tax:2697049
32 737-744 Chemical denotes heparin MESH:D006493
33 749-760 Chemical denotes LMW heparin MESH:D006495
34 875-886 Chemical denotes LMW heparin MESH:D006495
35 919-926 Chemical denotes heparin MESH:D006493
36 931-942 Chemical denotes LMW heparin MESH:D006495
37 1009-1020 Chemical denotes LMW heparin MESH:D006495
38 1060-1074 Disease denotes thromboembolic MESH:D013923
39 1092-1100 Disease denotes COVID-19 MESH:C000657245
40 1139-1150 Chemical denotes LMW heparin MESH:D006495
41 1199-1207 Disease denotes COVID-19 MESH:C000657245
42 1299-1308 Disease denotes mortality MESH:D003643
43 1318-1326 Species denotes patients Tax:9606

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-98 Sentence denotes Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications:
T2 99-132 Sentence denotes A Review of the Current Evidence.
T3 133-245 Sentence denotes The impact of the COVID-19 pandemic has been dramatic worldwide, with China, Italy, and now US at its epicenter.
T4 246-385 Sentence denotes Researchers and clinicians are studying and testing different approaches in the attempt to prevent the infection and minimize its severity.
T5 386-599 Sentence denotes Major efforts are focused on optimizing mechanical ventilation, antiviral, and supportive treatment; however, the role of heparin and low molecular weight (LMW) heparin in this setting has been largely overlooked.
T6 600-1101 Sentence denotes This review summarizes the available evidence about the role of heparan sulfate as a key entry mechanism for SARS-CoV-2; the efficacy of heparin and LMW heparin in counteracting its entry into the cell, the recent experimental findings obtained in in vitro studies using the LMW heparin enoxaparin Inhixa®, the role of heparin and LMW heparin in modulating the cytokine storm, and the evidence for the use of LMW heparin in the prevention and treatment of the thromboembolic complications of COVID-19.
T7 1102-1208 Sentence denotes The available evidence suggests that LMW heparin appears as a promising tool in the treatment of COVID-19.
T8 1209-1381 Sentence denotes Whether its systematic use is associated with a reduction in complications and ultimately mortality of these patients is being tested in several studies starting worldwide.

LitCovid-PD-GlycoEpitope

Id Subject Object Predicate Lexical cue glyco_epitope_db_id
T1 664-679 GlycoEpitope denotes heparan sulfate http://www.glycoepitope.jp/epitopes/EP0086

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 62-76 Phenotype denotes Thromboembolic http://purl.obolibrary.org/obo/HP_0001907
T2 961-975 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T3 1060-1074 Phenotype denotes thromboembolic http://purl.obolibrary.org/obo/HP_0001907